Clinerion, a real-world data solutions firm focusing on improving efficiency in clinical trials across geographies, and Patient iP, a health data and analytics company providing patient data insights to accelerate and transform clinical research within the United States, are partnering to improve clinical trial design, site selection and patient enrollment.	 	The companies will collaborate using Clinerion’s intelligent, patented Patient Network Explorer platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment on a global scale. Clinerion aggregates healthcare information across institutions and geographies from their global network of partner hospitals, creating one single comprehensive real-time view. Clinerion’s network currently includes more than 17 million real time patient lives, with an additional 55 million lives contracted and in implementation, across more than 100 hospitals in the Americas, Europe and Asia. Used in combination with Patient iP’s platform which contains more than 16 million ambulatory electronic medical records (EMR) across 5,000 practice sites, the partnership will bring remarkable improvements to clinical trials.	 	“Patient iP and Clinerion, as alliance partners, are a partnership of providers providing similar services, with a complementary geographic footprint. The creation of a network of Clinerion alliance partners establishes a new, global and comprehensive, service resource for actionable patient data insights for clinical research,” says Ian Rentsch, CEO of Clinerion. “We are happy to bring the international footprint of our hospital network to the benefit of Patient iP’s clients. At the same time, this collaboration will broaden our current ability to service clients with real-world data from the USA. Our offerings complement each other well.”	 	“Patient iP is excited about the potential that a collaboration with Clinerion brings to the patient qualification space. Our combined focus on providing opportunities for the right patient at the right time creates a strength that is difficult to match,” said Michael Margiotta, Chairman, Founder and CEO of Patient iP. “Our complementary technologies and global reach will now enable both Patient iP and Clinerion to view patient populations from a much more diverse and inclusive perspective than we are able to do independently of each other and thus service our customers better than ever.”	 	 	

	 	Clinerion accelerates clinical research and medical access of medicines for patients using proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and patient search and identification, and generates real-world evidence for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and the gaining of time savings in patient recruitment. Clinerion’s solutions enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic patient records which remain under the full control of participating hospitals while complying with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.	Clinerion website: 

	 	For more information, please contact:	Le Vin Chin	Director, Head of Marketing and Communications	Clinerion Ltd	Margarethenstrasse 47, CH-4053 Basel, Switzerland	Tel.: +41 61 865 60 54	

	 	The patented Patient iP data analytics platform provides unique value for the clinical research industry. Using a cloud-based infrastructure, the company leverages aggregated patient data to streamline and accelerate clinical trial design, site selection and participant matching to bring new therapies to market faster and more cost effectively. Deployed in concert, Patient iP’s award-winning technology and expansive daTAscapeTM enhance recruitment efforts, increase performance predictability, and maximize research yield given a focus on the untapped community-based patient market.	For more information, visit us at 

.	 	For more information, please contact:	Michael Margiotta	CEO	Patient iP	Rochester, NY	Tel.: +1 844 845 4413	contact@patientip.com